News

The patient study is now fully recruited

22 April, 2022

Chordate Medical estimates that a sufficient number of patients have been recruited for the study on migraine which is being carried out in Germany and Finland - and that the number of patients prescribed by the study design has thus been met.

The main purpose of the patient study, which began in 2018, was from the beginning to enable a CE marking of the company's preventive treatment of chronic migraine. Since Chordate already in May 2021 received the CE marking on interim data from the same study, the main purpose was fulfilled, however, a positive result from the patient study is still extremely important for the continued marketing activities. The goal is to get a scientific article published. The article is expected to be completed and submitted for scientific review no earlier than the end of the third quarter of 2022, as the last patient will now leave the study in July.

"An article in a scientific journal will support our market positioning and our sales work in all selected markets, including countries outside the EU", says Anders Weilandt, CEO of Chordate.

The international patient study on the patented treatment method K.O.S against chronic migraine began in 2018. The study, which is carried out at nine clinics in Germany and Finland, was paused due to the covid-19 pandemic in 2020 but resumed intermittently in 2021 when the pandemic progression allowed.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medical's share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com. 
Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, ca@vhcorp.se.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Fler Nyheter

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate's share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

 

Contact us

The information is handled according to our  privacy policy.